Janux Therapeutics reports Q3 2026 results and doses first patient in JANX013 combination study
Janux Therapeutics announced its third‑quarter 2026 financial results and said the first patient was dosed in a Phase 1 study of JANX013 combined with JANX007. The company also confirmed that initial clinical data from the Phase 1 healthy‑volunteer study of JANX011 will be presented on November 9, 2026. The release highlighted ongoing Phase 1b development of JANX007 and continued enrollment in the JANX014 study for metastatic castration‑resistant prostate cancer.
Why it matters
The results show Janux holding a cash balance of roughly $945‑$967 million, providing runway for its multiple clinical programs. The upcoming data presentation on November 9 could act as a catalyst for the stock, while the net loss indicates continued investment in R&D.
Key facts
- 1First patient was dosed in the Phase 1 study evaluating JANX013 in combination with JANX007. stocktitan.net
- 2Initial clinical data from the Phase 1 healthy‑volunteer study of JANX011 will be presented during an investor webcast on November 9, 2026. stocktitan.net
Open questions
- Cash and cash equivalents and short‑term investments reported as $945.7 million versus $966.6 million as of September 30, 2026.
- Research and development expenses reported as $30.6 million versus $34.6 million for the quarter.
- General and administrative expenses reported as $10.0 million versus $10.6 million for the quarter.
- Net loss reported as $21.6 million versus $24.3 million for the quarter.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.